Rejection and graft-versus-host disease: analysis of pretransplantation factors
| Factor . | Rejectors (n = 9) . | Nonrejectors (n = 35) . | P value (rejection) . | Grades II-IV GVHD (n = 17) . | Grades 0-I GVHD (n = 19) . | P value (GVHD) . |
|---|---|---|---|---|---|---|
| Male patient | 7/9 (78%) | 24/35 (67%) | .70 | 11/17 (65%) | 13/19 (68%) | .81 |
| Male donor | 4/9 (44%) | 21/35 (58%) | .47 | 9/17 (53%) | 12/19 (63%) | .54 |
| Intensive prior therapy4-150 | 1/9 (11%) | 31/35 (86%) | < .0001 | 15/17 (88%) | 16/19 (84%) | 1.0 |
| Donor age in years | 48 (40-72) | 57 (33-73) | .80 | 53 (33-73) | 58 (38-65) | .78 |
| Patient age in years | 54 (40-71) | 56 (31-72) | .76 | 56 (31-70) | 57 (36-72) | .87 |
| CD34+ cell dose × 106/kg | 9.1 (3.8-15.1) | 6.9 (3.1-17.5) | .51 | 6.4 (3.3-16.1) | 6.9 (3.1-17.5) | .57 |
| CD3+ cell dose × 108/kg | 3.3 (1.0-4.5) | 3.4 (0.7-8.3) | .58 | 3.6 (0.7-7.2) | 3.1 (0.8-8.3) | .86 |
| Diagnosis of CML | 4/9 (44%) | 4/35 (11%) | .04 | 2/17 (12%) | 3/19 (16%) | 1.0 |
| Factor . | Rejectors (n = 9) . | Nonrejectors (n = 35) . | P value (rejection) . | Grades II-IV GVHD (n = 17) . | Grades 0-I GVHD (n = 19) . | P value (GVHD) . |
|---|---|---|---|---|---|---|
| Male patient | 7/9 (78%) | 24/35 (67%) | .70 | 11/17 (65%) | 13/19 (68%) | .81 |
| Male donor | 4/9 (44%) | 21/35 (58%) | .47 | 9/17 (53%) | 12/19 (63%) | .54 |
| Intensive prior therapy4-150 | 1/9 (11%) | 31/35 (86%) | < .0001 | 15/17 (88%) | 16/19 (84%) | 1.0 |
| Donor age in years | 48 (40-72) | 57 (33-73) | .80 | 53 (33-73) | 58 (38-65) | .78 |
| Patient age in years | 54 (40-71) | 56 (31-72) | .76 | 56 (31-70) | 57 (36-72) | .87 |
| CD34+ cell dose × 106/kg | 9.1 (3.8-15.1) | 6.9 (3.1-17.5) | .51 | 6.4 (3.3-16.1) | 6.9 (3.1-17.5) | .57 |
| CD3+ cell dose × 108/kg | 3.3 (1.0-4.5) | 3.4 (0.7-8.3) | .58 | 3.6 (0.7-7.2) | 3.1 (0.8-8.3) | .86 |
| Diagnosis of CML | 4/9 (44%) | 4/35 (11%) | .04 | 2/17 (12%) | 3/19 (16%) | 1.0 |
For abbreviations, see Tables 1 and 2.
Data are presented as n (%) or median (range). Rejection analysis includes 44 patients who received low-dose TBI/CSP/MMF and excludes patient FH14726, who also received fludarabine.
Intensive prior therapy includes prior autograft, prior intensive chemotherapy for acute leukemia, or more than 3 cycles of a fludarabine-containing regimen.